Histopathological and molecular markers in prognostic evaluation of salivary mucoepidermoid carcinoma

doi:10.19438/j.cjoms.2018.04.016

Abstract

Abstract: Mucoepidermoid carcinoma (MEC） is the most common salivary gland malignancies, which used to be classified as mucoepidermoid tumor. Although MEC is composed basically of 3 different cell types: a mucin-producing cell, an epidermoid cell, and an intermediate cell, MEC may have different biological behaviors, which can be divided into low, moderate, and high grade. It is important to distinguish the histopathologic grade, in order to make appropriate treatment plan. In recent years, several prognostic molecular markers have been discovered, which are expected to be combined with the traditional histopathological classification to form a rating system for improving prognosis assessment of MEC.

Key words: Mucoepidermoid carcinoma, Fusion gene, MECT1-MAML2, Salivary gland

CLC Number:

R739.8

WANG Yang, TIAN Zhen. Histopathological and molecular markers in prognostic evaluation of salivary mucoepidermoid carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(4): 376-381.

References

[1] El-Naggar A, Chan J, Grandis J, et al.WHO classification of head and neck tumours[M]. Lyon, France: IARC, 2017: 163-164.
[2] McHugh CH, Roberts DB, El-Naggar AK, et al. Prognostic factors in mucoepidermoid carcinoma of the salivary glands[J]. Cancer, 2012, 118(16): 3928-3936.
[3] Seifert G, Sobin LH.The World Health Organization's histological classification of salivary gland tumors. A commentary on the second edition[J]. Cancer, 1992, 70(2): 379-385.
[4] Auclair PL, Goode RK, Ellis GL.Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases[J]. Cancer, 1992, 69(8): 2021-2030.
[5] Brandwein MS, Ivanov K, Wallace DI, et al.Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading[J]. Am J Surg Pathol, 2001, 25(7): 835-845.
[6] Batsakis JG, Luna MA.Histopathologic grading of salivary gland neoplasms: I. Mucoepidermoid carcinomas[J]. Ann Otol Rhinol Laryngol, 1990, 99(10 Pt 1): 835-838.
[7] Healey WV, Perzin KH, Smith L.Mucoepidermoid carcinoma of salivary gland origin. Classification, clinical-pathologic correlation, and results of treatment[J]. Cancer, 1970, 26(2): 368-388.
[8] Katabi N, Ghossein R, Ali S, et al.Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading[J]. Histopathology, 2014, 65(6): 793-804.
[9] Nordkvist A, Gustafsson H, Juberg-Ode M, et al.Recurrent rearrangements of 11q14-22 in mucoepidermoid carcinoma[J]. Cancer Genet Cytogenet, 1994, 74(2): 77-83.
[10] Tonon G, Modi S, Wu L, et al.t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway[J]. Nat Genet, 2003, 33(2): 208-213.
[11] Enlund F, Behboudi A, Andren Y, et al.Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors[J]. Exp Cell Res, 2004, 292(1): 21-28.
[12] Saade RE, Bell D, Garcia J, et al.Role of CRTC1/MAML2 translocation in the prognosis and clinical outcomes of mucoepidermoid carcinoma[J]. JAMA Otolaryngol Head Neck Surg, 2016, 142(3): 234-240.
[13] Chen Z, Chen J, Gu Y, et al.Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells[J]. Oncogene, 2014, 33(29): 3869-3877.
[14] Anzick SL, Chen WD, Park Y, et al.Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions[J]. Genes Chromosomes Cancer, 2010, 49(1): 59-69.
[15] Fehr A, Meyer A, Heidorn K, et al.A link between the expression of the stem cell marker HMGA2, grading, and the fusion CRTC1-MAML2 in mucoepidermoid carcinoma[J]. Genes Chromosomes Cancer, 2009, 48(9): 777-785.
[16] Okumura Y, Miyabe S, Nakayama T, et al.Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma[J]. Histopathology, 2011, 59(1): 90-97.
[17] Seethala RR, Dacic S, Cieply K, et al.A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas[J]. Am J Surg Pathol, 2010, 34(8): 1106-1121.
[18] Fonseca FP, Sena Filho M, Altemani A, et al.Molecular signature of salivary gland tumors: potential use as diagnostic and prognostic marker[J]. J Oral Pathol Med, 2016, 45(2): 101-110.
[19] Fehr A, Roser K, Heidorn K, et al.A new type of MAML2 fusion in mucoepidermoid carcinoma[J]. Genes Chromosomes Cancer, 2008, 47(3): 203-206.
[20] Nakayama T, Miyabe S, Okabe M, et al.Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma[J]. Mod Pathol, 2009, 22(12): 1575-1581.
[21] Behboudi A, Enlund F, Winnes M, et al.Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene[J]. Genes Chromosomes Cancer, 2006, 45(5): 470-481.
[22] Rotellini M, Paglierani M, Pepi M, et al.MAML2 rearrangement in Warthin's tumour: a fluorescent in situ hybridisation study of metaplastic variants[J]. J Oral Pathol Med, 2012, 41(8): 615-620.
[23] Fehr A, Roser K, Belge G, et al.A closer look at Warthin tumors and the t(11;19)[J]. Cancer Genet Cytogenet, 2008, 180(2): 135-139.
[24] Ishibashi K, Ito Y, Masaki A, et al.Warthin-like mucoepidermoid carcinoma: a combined study of fluorescence in situ hybridization and whole-slide imaging[J]. Am J Surg Pathol, 2015, 39(11): 1479-1487.
[25] Stenman G.Fusion oncogenes in salivary gland tumors: molecular and clinical consequences[J]. Head Neck Pathol, 2013, 7(Suppl 1):S12-S19.
[26] Moller E, Stenman G, Mandahl N, et al.POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands[J]. J Pathol, 2008, 215(1): 78-86.
[27] Kim S, Lim B, Kim J.EWS-Oct-4B, an alternative EWS-Oct-4 fusion gene, is a potent oncogene linked to human epithelial tumours[J]. Br J Cancer, 2010, 102(2): 436-446.
[28] Shiratsuchi H, Nakashima T, Hirakawa N, et al.beta-Catenin nuclear accumulation in head and neck mucoepidermoid carcinoma: its role in cyclin D1 overexpression and tumor progression[J]. Head Neck, 2007, 29(6): 577-584.
[29] Guo XL, Sun SZ, Wang WX, et al.Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands[J]. Int J Oral Maxillofac Surg, 2007, 36(4): 350-353.
[30] Ettl T, Stiegler C, Zeitler K, et al.EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis[J]. Hum Pathol, 2012, 43(6): 921-931.
[31] Nakano T, Yamamoto H, Hashimoto K, et al.HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status[J]. Histopathology, 2013, 63(3): 378-392.
[32] Ou Yang KX, Liang J, Huang ZQ.Association of clinicopathologic parameters with the expression of inducible nitric oxide synthase and vascular endothelial growth factor in mucoepidermoid carcinoma[J]. Oral Dis, 2011, 17(6): 590-596.
[33] Demasi APD, Silva CAB, Silva AD, et al.Expression of the vascular endothelial growth factor and angiopoietins in mucoepidermoid carcinoma of salivary gland[J]. Head Neck Pathol, 2011, 6(1): 10-15.
[34] Skalova A, Lehtonen H, von Boguslawsky K, et al. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections[J]. Human Pathol, 1994, 25(9): 929-935.
[35] Kiyoshima T, Shima K, Kobayashi I, et al.Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands[J]. Oral Oncol, 2001, 37(3): 315-322.